Organizations Filed Purposes:
RUNX1 FOUNDATION'S MISSION STATEMENT IS TO PROVIDE GRANTS FOR RELEVANT RESEARCH PROJECTS IN FINDING A CURE FOR FPD/AML, ALONG WITH SUPPORTING PATIENTS IN THE FPD/AML COMMUNITY BY PROVIDING A FORUM IN WHICH TO HELP CONNECT, INFORM AND EDUCATE PATIENTS AND RAISE PUBLIC AWARENESS REGARDING THE DISORDER.
2019 FAMILIAL RESEARCH AWARD. IN CO-FUNDING PARTNERSHIP WITH ALEX'S LEMONADE STAND FOUNDATION (ALSF), RUNX1 RESEARCH PROGRAM GRANTED $600,000 FOR RESEARCH GRANTS AWARDED TO: DR. MORTIMER PONCZ, CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP), 'DRUG SCREEN FOR FPD/AML THERAPEUTICS; DR. ANUPRIYA AGARWAL, OREGON HEALTH & SCIENCE UNIVERSITY (OHSU), 'ROLE OF INFLAMMATORY MICROENVIRONMENT IN CLONAL EVOLUTION AND PROGRESSION FROM FPD TO AML; DR. RAVI MAJETI, STANFORD UNIVERSITY, 'CHARACTERIZATION OF PRE-LEUKEMIA ASSOCIATED WITH FAMILIAL RUNX1 MUTATIONS; DR. ALAN B. CANTOR, BOSTON CHILDREN'S HOSPITAL, 'PHARMACOLOGIC ENHANCEMENT OF RESIDUAL WILD TYPE RUNX1 PROTEIN ACTIVITY IN RUNX1-FPD; DR. EIRINI PAPAPETROU, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, 'IDENTIFYING THERAPEUTIC TARGETS TO PREVENT PROGRESSION OF FAMILIAL RUNX1 DISORDER TO AML USING NOVEL IPSC MODELS; AND DR. LEONARD I. ZON, BOSTON CHILDREN'S HOSPITAL, 'MODELING RUNX1-ASSOCIATED CLONAL HEMATOPOIETIC DISORDERS IN ZEBRAFISH'.
RUNX1 FOUNDATION AWARDS. INDEPENDENT GRANTS FUNDED SOLELY BY RRP, DR. NANCY SPECK AT THE UNIVERSITY OF PENNSYLVANIA CONTINUES HER WORK, TO DEVELOP A MOUSE MODEL OF RUNX1-FPD BY INTRODUCING MUTATIONS INTO THE RUNX1 GENE THAT LOWER THE EFFECTIVE RUNX1 DOSAGE IN THE MOUSE. THIS MOUSE MODEL WILL BE AN ESSENTIAL TOOL FOR THE PRE-CLINICAL DEVELOPMENT OF ANY THERAPY PRIOR TO A FIRST-IN-HUMAN CLINICAL TRIAL IN RUNX1-FPD PATIENTS.
2019 TRANSLATIONAL RESEARCH. IN CO-FUNDING PARTNERSHIP WITH THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS), RUNX1 RESEARCH PROGRAM GRANTED $200,000 FOR TRANSLATIONAL LEUKEMIA RESEARCH RELATED TO THE GERMLINE RUNX1 DISORDER. DR. BENJAMIN EBERT, HARVARD MEDICAL SCHOOL, 'INTERACTION OF RUNX1 AND THE COHESIN COMPLEX IN MEGAKARYOCYTE DEVELOPMENT AND MYELOID DISEASE'. BY GENERATING A MOUSE MODEL TO STUDY THE MUTATIONS, HEMATOPOIESIS AND LEUKEMIA PROGRESSION. HIS RESEARCH INCLUDES AN EVALUATION OF THE INHIBITORS OF CDK8, A MEMBER OF THE TRANSCRIPTIONAL MEDIATOR COMPLEX, FOR THEIR ACTIVITY AND MECHANISM OF ACTION IN THE CONTEXT OF RUNX1 AND/OR STAG2 MUTATIONS. RESEARCHER DR. GUY SAUVAGEAU, UNIVERSITY OF MONTREAL 'RUNX1 MUTATIONS THAT CONFER EXQUISITE SENSITIVITY TO GLUCOCORTICOIDS'. HE IS RESEARCHING HOW GLUCOCORTICOIDS INHIBIT THE GROWTH OF RUNX1 MUTANT AML CELLS, AND IS TESTING THE ABILITY OF GLUCOCORTICOIDS TO INHIBIT AML IN A MOUSE MODEL. DR NIMER'S PROJECT ENTITLED, 'EPIGENETIC-MODIFYING ENZYMES IN RUNX1-FPD' WILL EVALUATE THE ABILITY OF INHIBITORS OR ACTIVATORS OF EPIGENETIC GENE REGULATION TO PROMOTE THE DIFFERENTIATION, OR INHIBIT THE SELF-RENEWAL, PROLIFERATION, AND SURVIVAL OF RUNX1 MUTANT HEMATOPOIETIC CELLS DERIVED FROM CULTURES OF HUMAN-INDUCED PLURIPOTENT STEM CELLS (IPSCS)."
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Dr Katrin Ericson | EXECUTIVE DIRECTOR | 40 | $329,511 |
| Monica Babich | CO-DIRECTOR | 15 | $0 |
| Timothy Babich | CO-DIRECTOR | 15 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202042539349300549_public.xml